Company intelligence / Profile preview

IMBiotechnologies

Edmonton, Alberta, Canadaimbiotechnologies.com ↗

Ownership: Private
Development stage: Other

Overview

IMBiotechnologies' lead product, Ekobi Embolization Microspheres, is a first-in-class biodegradable and ultrasound-detectable embolic agent for use in embolotherapy. The microspheres are used to selectively block blood flow to target tissues such as tumors or hypertrophic organs. They are made from PLGA and fully biodegrade within 4–6 months. Clinical results highlight their safety profile and effectiveness in treating both malignant and benign conditions through minimally invasive procedures[2][3].

Therapeutic areas: GastroenterologyMen's HealthCardiovascularOncologyWomen's Health
Modalities: DeviceBiodegradable embolic agent (Ekobi Microspheres)
Industry: Therapeutic Medical Devices

Partnerships

Med Alliance International LLC [5]

Beyond the preview

Go deeper on IMBiotechnologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMBiotechnologies.

Explore the full profile